e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan®
Y. Tamura, T. Ono, K. Fukuda, T. Satoh, S. Sasayama (Tokyo, Kyoto, Japan)
Source:
Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Session:
Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Session type:
Thematic Poster Session
Number:
4084
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Tamura, T. Ono, K. Fukuda, T. Satoh, S. Sasayama (Tokyo, Kyoto, Japan). EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan®. Eur Respir J 2013; 42: Suppl. 57, 4084
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source: Eur Respir J 2015; 45: 1303-1313
Year: 2015
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Afterload reduction governs improvement in RV systolic function and ventriculo-arterial adaptation in patients with pulmonary arterial hypertension (PAH) undergoing rapid dose escalation of treprostinil
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept